Skip to main content
SpringerLink
Log in

The determination of relationship between “excision repair cross-complementing group 1” (ERCC1) gene T19007C and C8092A single nucleotide polymorphisms and clinicopathological parameters in non-small cell lung cancer

  • Published:
Molecular Biology Reports Aims and scope Submit manuscript

Abstract

DNA repair plays a key role in prevention of carcinogenesis and one of the most important DNA repair mechanisms is nucleotide excision repair (NER) pathway. This pathway includes a number of genes such as excision repair cross-complementing group 1 (ERCC1) gene which are responsible for the 5′ incision of damaged DNA. A reduced DNA repair capacity associated with ERCC1 mRNA level has been observed in lung carcinogenesis. Two single nucleotide polymorphisms (SNPs) in ERCC1 gene, T19007C (rs11615) and C8092A (rs3212986), reportedly predict to affect the mRNA of ERCC1 in non-small cell lung cancer (NSCLC). To examine the role of two common SNPs in ERCC1 gene further, we conducted this study where 80 cases histopatologically diagnosed as NSCLC were genotyped. Genomic DNA was extracted from formalin-fixed, paraffin embedded tissues and two SNPs were analyzed using real-time PCR. The distributions of TT, TC, and CC genotypes of the T19007C SNP were 40, 44 and 16%, respectively. Significantly increased frequency of the patients carrying at least one 19007C allele was observed in early stage compared to advanced stage (P = 0.002). And also, the frequency of TC and CC genotypes significantly increased in younger patients compared to older patients (P = 0.035). Regarding C8092A SNP, the distribution of CC, CA, and AA genotypes was 38, 51 and 11%, respectively. There was no significant difference in the genotype distribution between C8092A SNP and clinicopathological parameters. This study indicated that harboring at least one 19007C allele may have protective effect in NSCLC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. World Health Organization (2009) Fact Sheet no: 297. http://www.who.int/cancer/en. Accessed Feb 2009

  2. Ministry of Health Republic of Turkey (2009) Cancer statistics in Turkey. http://www.kanser.gov.tr. Accessed Dec 2010

  3. Ahlquist DA (2010) Molecular detection of colorectal neoplasia. Gastroenterology 138:2127–2139

    Article  PubMed  CAS  Google Scholar 

  4. Da Silva L, Lakhani SR (2010) Pathology of hereditary breast cancer. Mod Pathol 23:46–51

    Article  Google Scholar 

  5. Chirieac LR, Dacic S (2010) Targeted therapies in lung cancer. Surg Pathol Clin 3:71–82

    Article  PubMed  Google Scholar 

  6. Hoeijmakers JH (2001) Genome maintenance mechanisms for preventing cancer. Nature 411:366–374

    Article  PubMed  CAS  Google Scholar 

  7. Shuck SC, Short EA, Turchi JJ (2008) Eukaryotic nucleotide excision repair: from understanding mechanisms to influencing biology. Cell Res 18:64–72

    Article  PubMed  CAS  Google Scholar 

  8. Park CH, Bessho T, Matsunaga T, Sancar A (1995) Purification and characterization of the XPF-ERCC1 complex of human DNA repair excision nuclease. J Biol Chem 270:22657–22660

    Article  PubMed  CAS  Google Scholar 

  9. Niedernhofer LJ, Odijk H, Budzowska M, van Drunen E, Maas A, Theil AF et al (2004) ERCC1–XPF is required to resolve DNA interstrand cross-link-induced double-strand breaks. Mol Cell Biol 24:5776–5787

    Article  PubMed  CAS  Google Scholar 

  10. Cummings M, Higginbottom K, McGurk GJ, Wong OG, Köberle B, Oliver RT et al (2006) XPA versus ERCC1 as chemosensitising agents to cisplatin and mitomycin C in prostate cancer cells: role of ERCC1 in homologous recombination repair. Biochem Pharmacol 72:166–175

    Article  PubMed  CAS  Google Scholar 

  11. Park CJ, Choi BS (2006) The protein shuffle. Sequential interactions among components of the human nucleotide excision repair pathway. FEBS J 273:1600–1608

    Article  PubMed  CAS  Google Scholar 

  12. Isla D, Sarries C, Rosell R, Alonso G, Domine M, Taron M et al (2004) Single nucleotide polymorphisms and outcome in docetaxel cisplatin treated advanced NSCLC. Ann Oncol 8:1194–1203

    Article  Google Scholar 

  13. Zhou W, Liu G, Park S, Wang Z, Wain JC, Lynch TJ (2005) Gene-smoking interaction associations for the ERCC1 polymorphisms in the risk of lung cancer. Cancer Epidemiol Biomarkers Prev 14:491–496

    Article  PubMed  CAS  Google Scholar 

  14. Zienolddiny S, Campa D, Lind H, Ryberg D, Skaug V, Stageland L et al (2006) Polymorphisms of DNA repair genes and risk of non-small lung cancer. Carcinogenesis 27:560–567

    Article  PubMed  CAS  Google Scholar 

  15. Takenaka T, Yano T, Kiyohara C, Miura N, Kouso H, Ohba T et al (2009) Effects of Excision Repair Cross-Complementation Group 1 (ERCC1) single nucleotide polymorphisms on the prognosis of non-small cell lung cancer patients. Lung Cancer 67:101–107

    Article  Google Scholar 

  16. Yu JJ, Lee KB, Mu C, Li Q, Abernathy TV et al (2000) Comparison of two human ovarian carcinoma cell lines (A2780/CP70 and MCAS) that are equally resistant to platinum, but differ at codon 118 of the ERCC1 gene. Int J Oncol 16:555–560

    PubMed  CAS  Google Scholar 

  17. Chen P, Wiencke J, Aldape K, Kesler-Diaz A, Miike R, Kelsey K et al (2000) Association of an ERCC1 polymorphism with adult-onset glioma. Cancer Epidemiol Biomarkers Prev 9:843–847

    PubMed  CAS  Google Scholar 

  18. Travis WD, Brambilla E, Müller-Hermelink HK, Haris CC (2004) Tumours of the lung. In: World Health Organization Classification of Tumours: Pathology and Genetics—Tumours of Lung, Pleura, Thymus, and Heart. Lyon, pp 10–11

  19. Cheng L, Spitz MR, Hong WK, Wei Q (2000) Reduced expression levels of nucleotide excision repair genes in lung cancer: a case-control analysis. Carcinogenesis 21:1527–1530

    Article  PubMed  CAS  Google Scholar 

  20. Spitz MR, Wei QY, Dong Q, Amos CI, Wu XF (2003) Genetic susceptibility to lung cancer: the role of DNA damage and repair. Cancer Epidemiol Biomarkers Prev 12:689–698

    PubMed  CAS  Google Scholar 

  21. Butkiewicz D, Rusin M, Sikora B, Lach A, Chorąży M (2010) An association between DNA repair gene polymorphisms and survival in patients with resected non-small cell lung cancer. Mol Biol Rep. doi:10.1007/s11033-010-0674-1

  22. Zhou W, Gurubhagavatula S, Liu G, Park S, Neuberg DS, Wain JC et al (2004) Excision Repair Cross-Complementation Group 1 polymorphism predicts overall survival in advanced NSCLC patients treated with platinum-based chemotherapy. Clin Cancer Res 10:4939–4943

    Article  PubMed  CAS  Google Scholar 

  23. Tibaldi C, Giovannetti E, Vasile E, Mey V, Laan AC, Nannizzi S et al (2008) Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine-cisplatin treated advanced NSCLC patients. Clin Cancer Res 14:1797–1803

    Article  PubMed  CAS  Google Scholar 

  24. Kiyohara C, Yoshimasu K (2007) Genetic polymorphisms in the nucleotide excision repair pathway and lung cancer risk: a meta-analysis. Int J Med Sci 4:59–71

    PubMed  CAS  Google Scholar 

  25. Wei Q, Cheng L, Amos C (2000) Repair of tobacco carcinogen-induced DNA adducts and lung cancer risk: a molecular epidemiologic study. J Natl Cancer Inst 92:1764–1772

    Article  PubMed  CAS  Google Scholar 

  26. Matullo G, Dunning AM, Guarrera S, Baynes C, Polidoro S, Garte S et al (2006) DNA repair polymorphisms and cancer risk in non-smokers in a cohort study. Carcinogenesis 27:997–1007

    Article  PubMed  CAS  Google Scholar 

  27. Kalikaki A, Kanaki M, Vassalou H, Souglakos J, Voutsina A, Georgoulias V et al (2009) DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small cell lung cancer. Clin Lung Cancer 10:118–123

    Article  PubMed  CAS  Google Scholar 

  28. Garnis C, Lockwood WW, Vucic E, Ge Y, Girard L, Minna JD et al (2006) High resolution analysis of non-small cell lung cancer cell lines by whole genome tiling path array CGH. Int J Cancer 118:1556–1564

    Article  PubMed  CAS  Google Scholar 

  29. Yang IA, Relan V, Wright CM, Davidson MR, Sriram KB, Savarimuthu Francis SM et al (2011) Common pathogenic mechanisms and pathways in the development of COPD and lung cancer. Expert Opin Ther Targets 15:439–456

    PubMed  CAS  Google Scholar 

  30. Kitamura H, Yazawa T, Okudela K, Shimoyamada H, Sato H (2008) Molecular and genetic pathogenesis of lung cancer: differences between small-cell and non-small-cell carcinomas. Open Pathol J 2:106–114

    Article  CAS  Google Scholar 

  31. Kalikaki A, Koutsopoulos A, Trypaki M, Souglakos J, Stathopoulos E, Georgoulias V et al (2008) Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC. Br J Cancer 99:923–929

    Article  PubMed  CAS  Google Scholar 

  32. Linardou H, Dahabreh IJ, Bafaloukos D, Kosmidis P, Murray S (2009) Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC. Nat Rev Clin Oncol 6:352–366

    Article  PubMed  CAS  Google Scholar 

  33. Riely GJ, Politi KA, Miller VA, Pao W (2006) Update on epidermal growth factor receptor mutations in non-small cell lung cancer. Clin Cancer Res 12:7232–7241

    Article  PubMed  CAS  Google Scholar 

  34. Han SW, Kim TY, Jeon YK, Hwang PG, Im SA, Lee KH et al (2006) Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation. Clin Cancer Res 12:2538–2544

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Biology, Pamukkale University, School of Medicine, Morfoloji Binasi Kat: 3, 20070, Kinikli, Denizli, Turkey

    Esin Koç, Vildan Caner & Gülseren Bağcı

  2. Department of Pathology, Yedikule Chest Diseases Hospital, Zeytinburnu, İstanbul, Turkey

    Nur Büyükpınarbaşılı

  3. Department of Medical Genetics, Pamukkale University, School of Medicine, Doktorlar Cad. Kat: 3, No: 42, Bayramyeri, Denizli, Turkey

    Emre Tepeli & G. Ozan Çetin

  4. Department of Pathology, Pamukkale University, School of Medicine, Morfoloji Binasi Kat: 1, 20070, Kinikli, Denizli, Turkey

    Nilay Şen Türk

Authors
  1. Esin Koç
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Vildan Caner
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Nur Büyükpınarbaşılı
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Emre Tepeli
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Nilay Şen Türk
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. G. Ozan Çetin
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Gülseren Bağcı
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Vildan Caner.

Additional information

All authors have equally contributed to this manuscript.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Koç, E., Caner, V., Büyükpınarbaşılı, N. et al. The determination of relationship between “excision repair cross-complementing group 1” (ERCC1) gene T19007C and C8092A single nucleotide polymorphisms and clinicopathological parameters in non-small cell lung cancer. Mol Biol Rep 39, 375–380 (2012). https://doi.org/10.1007/s11033-011-0748-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11033-011-0748-8

Keywords

Search

Navigation